Yantai Dongcheng Biochemicals (002675) Announces Acquisition of Rongcheng Medicine's Liver Function Assessment Nuclear Medicine Product, with CEC Capital Serving as Exclusive Financial Advisor to the Seller

On February 21, 2024, Yantai Dongcheng Biochemicals (002675) announced that its wholly-owned subsidiary, Yitai Pharmaceutical, intends to purchase the 99mTc-GSA injection and GSA cold kit (hereinafter referred to as the "target product") held by Rongcheng Medicine, buying out and obtaining all rights, ownership, and interests of the target product. This transaction will help Yantai Dongcheng Biochemicals increase the variety of radionuclide drug products, enrich its product pipeline, broaden sources of income and profits, and meet the needs of the company's strategic development.

CEC Capital served as the exclusive financial advisor to Rongcheng Medicine in this transaction.

Founded in 1998 and successfully listed on the Shenzhen Stock Exchange in May 2012, Yantai Dongcheng Biochemicals covers four major areas: biochemical APIs, traditional Chinese medicines, chemical drugs, and nuclear medicines. It is a large pharmaceutical enterprise group integrating drug research and development, production, and sales. Yitai Pharmaceutical, a wholly-owned subsidiary of Yantai Dongcheng Biochemicals, focuses on the nuclear medicine and health industry, mainly engaged in research and development of new technologies and products in the field of biopharmaceuticals, as well as the transformation of achievements.